Method for predicting response of patients with malignant diseases to immunotherapy
OwnerDimo Dietrichinventor
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for predicting the response of a patient with a malignant disease to immunotherapy with a pharmaceutical compound that is designed to inhibit an immunoregulatory effect of an immune checkpoint selected from cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and its ligands Cluster of differentiation 80 (CD80) and Cluster of Differentiation 86 (CD86). The methods are based on a DNA methylation analysis of the CTLA4 gene of cells of the malignant disease and/or T lymphocytes interacting with said cells of the malignant disease.
Claims6
A method for treating a human subject afflicted with malignant melanoma with an antibody, comprising
- administering to the human subject an effective amount of a monoclonal antibody that specifically binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby inhibiting binding of CD80 and/or CD86 to CTLA4,
- wherein a CpG dinucleotide in a promoter region of the CTLA4 gene is known, from a DNA methylation analysis of a sample of the subject's melanoma cells and/or T lymphocytes interacting with the melanoma cells, level less than that of a refence value in the subject's melanoma cells and/or T lymphocytes interacting with the subject's melanoma cells.
A method for treating a human subject afflicted with malignant melanoma comprising
- administering to the subject a therapeutically effective dosing regimen of ipilimumab, wherein a promoter region of the CTLA4 gene in the subject's melanoma cells or T lymphocytes interacting with the melanoma cells is known, from a DNA methylation analysis of a sample of the subject's melanoma cells and/or T lymphocytes interacting with the melanoma cells, to have a mean DNA methylation level less than that of a reference value.
A method for treating a human subject afflicted with malignant melanoma comprising
- administering to the subject a therapeutically effective dosing regimen of tremelimumab, wherein a promoter region of the CTLA4 gene in the subject's melanoma cells or T lymphocytes interacting with the melanoma cells is known, from a DNA methylation analysis of a sample of the subject's melanoma cells and/or T lymphocytes interacting with the melanoma cells, to have a mean DNA methylation level less than that of a reference value.
Dependencies are inferred from the claim text.